Cancer Management & Treatment | Cancer Research & Drug Trials
网页Cancer Therapy Advisor offers the latest cancer management and treatment info, cancer research news, and more for oncologists and medical professionals.
Cancer Management - Cancer Therapy Advisor
网页Cancer Therapy Advisor’s cancer treatment resources now include the most recent guideline-based information to inform oncologists and oncology professionals about therapy selection for optimal ...
Rybrevant Plus Chemo Approved for Previously Treated
网页20 小时之前 · The US Food and Drug Administration (FDA) has approved a new indication for Rybrevant (amivantamab-vmjw). The bispecific antibody is now approved for use in combination with carboplatin and ...
ASCO 2024: Improving Outcomes in Metastatic Breast Cancer
网页2024年6月18日 · Research presented at the ASCO Annual Meeting 2024 highlighted treatments that may improve outcomes for patients with metastatic breast cancer. In the phase 3 postMONARCH trial, abemaciclib plus ...
Nivolumab Plus Ipilimumab in Advanced Melanoma: Potential for …
网页4 天之前 · The 10-year MSS rates were 52% with the combination, 44% with nivolumab alone, and 23% with ipilimumab alone. The differences between OS and MSS suggest that patients with advanced melanoma are ...
Malignant Ascites: Diagnosis and Management - Cancer Therapy …
网页2015年4月27日 · Malignant Ascites: Diagnosis and Management. Ascites refers to fluid that accumulates within the peritoneal cavity. Although ascites is most commonly observed in patients with cirrhosis and ...
Magnesium and Cancer - Cancer Therapy Advisor
网页2017年8月24日 · Magnesium and Cancer. Andrea S. Blevins Primeau, PhD, MBA. |. August 24, 2017. Magnesium is a critical mineral that is involved in over 600 enzymatic reactions, including those important for brain ...
Phase 1 Trials: What to Expect - Cancer Therapy Advisor
网页2020年3月13日 · The major benefit of participating in a phase 1 trial is the potential that the experimental therapy will shrink or stabilize the cancer. 2 Overall, it is estimated that approximately 7% to 11% of ...
Adding Atezolizumab to Chemo Improves Survival in Triple …
网页2023年12月14日 · The combination of atezolizumab and carboplatin improves survival outcomes over carboplatin alone in patients with metastatic triple-negative breast cancer (TNBC), according to research published ...
Targeted Therapies, Immunotherapies, Immunomodulators: A …
网页Since researchers developed the first modern cancer treatments in the 20th century, the number of strategies to treat cancer have exploded, now employing everything from small-molecule drugs ...